company background image

OpGen NasdaqCM:OPGN Stock Report

Last Price


Market Cap







06 Feb, 2023


Company Financials +

OPGN Stock Overview

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally.

OPGN fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance0/6
Financial Health3/6

My Notes


Notes are coming soon

OpGen, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for OpGen
Historical stock prices
Current Share PriceUS$1.74
52 Week HighUS$19.00
52 Week LowUS$1.66
1 Month Change-34.34%
3 Month Change-53.18%
1 Year Change-90.14%
3 Year Change-95.06%
5 Year Change-99.81%
Change since IPO-100.00%

Recent News & Updates

Recent updates

OpGen to raise $3.38M in direct stock offering

Sep 30

OpGen's subsidiary signs R&D agreement with FIND

Sep 20

Nasdaq grants extension to OpGen to regain compliance with minimum bid price requirement

Aug 31

OpGen launches sequencing services for infectious diseases in US

Aug 25

OpGen GAAP EPS of -$0.13 beats by $0.02, revenue of $1M in-line

Aug 11

OpGen reports preliminary revenue estimate for Q2 2022

Jul 08

OpGen gains on insider buying

Jun 15

OpGen submits 510(k) summary to FDA for Acuitas AMR Gene Panel for Isolates

Jun 07

OpGen reports prelim Q4 & FY20 revenue

Jan 13

OpGen subsidiary Curetis and Annar ink Unyvero distribution partnership for Colombia

Jan 05

OpGen launches $10M private placement

Nov 24

OpGen EPS misses by $0.04, beats on revenue

Nov 11

OpGen's subsidiary and collaborators secures German funding to develop such a molecular diagnostics platform

Oct 28

Shareholder Returns

OPGNUS BiotechsUS Market

Return vs Industry: OPGN underperformed the US Biotechs industry which returned 4.3% over the past year.

Return vs Market: OPGN underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is OPGN's price volatile compared to industry and market?
OPGN volatility
OPGN Average Weekly Movement30.7%
Biotechs Industry Average Movement12.1%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: OPGN is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 31% a week.

Volatility Over Time: OPGN's weekly volatility has increased from 19% to 31% over the past year.

About the Company

200195Oliver Schacht

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company’s products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers.

OpGen, Inc. Fundamentals Summary

How do OpGen's earnings and revenue compare to its market cap?
OPGN fundamental statistics
Market CapUS$10.10m
Earnings (TTM)-US$40.73m
Revenue (TTM)US$3.31m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OPGN income statement (TTM)
Cost of RevenueUS$13.22m
Gross Profit-US$9.91m
Other ExpensesUS$30.82m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date


Earnings per share (EPS)-7.01
Gross Margin-299.31%
Net Profit Margin-1,229.96%
Debt/Equity Ratio89.3%

How did OPGN perform over the long term?

See historical performance and comparison